Basic Information
| LncRNA/CircRNA Name | THOR |
| Synonyms | Lnc-THOR, ENSG00000226856 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | nasopharyngeal cancer |
| ICD-0-3 | C11 |
| Methods | qPCR, Western blot, RIP, Luciferase reporter assay, etc. |
| Sample | NPC cell lines (FaDu, SCC25, HN30, HN4, SCC4, Cal27, HN13 , HN12). NPC clinical tissues. |
| Expression Pattern | down-regulation |
| Function Description | Thus, our results demonstrate that lncRNA THOR could attenuate cisplatin sensitivity of NPC cells by enhancing cells stemness through promoting YAP transcriptional activity.Li, X. et al. indicated that lncRNA PFAL promotes lung fibrosis through CTGF by competitively binding miR-18a. And Ni, W. et al. showed that lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1. |
| Pubmed ID | 29959065 |
| Year | 2018 |
| Title | LncRNA THOR attenuates cisplatin sensitivity of nasopharyngeal carcinoma cells via enhancing cells stemness. |
External Links
| Links for THOR | GenBank HGNC NONCODE |
| Links for nasopharyngeal cancer | OMIM COSMIC |